Lidocaine Hcl And Epi
NDC Package 51662-1589-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Lidocaine Hcl And Epi is xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1589 and is authorized under FDA application NDA006488.

Identification & Billing

NDC Package Code
51662-1589-3
Package Description
25 POUCH in 1 CASE / 1 VIAL, MULTI-DOSE in 1 POUCH (51662-1589-2) / 50 mL in 1 VIAL, MULTI-DOSE (51662-1589-1)
Product Code
11-Digit Billing Format
51662158903
RxNorm Crosswalk
  • RxCUI: 1010751 - lidocaine HCl 1 % / EPINEPHrine 1:100,000 Injectable Solution
  • RxCUI: 1010751 - epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution
  • RxCUI: 1010751 - epinephrine (as epinephrine bitartrate) 1:100,000 / lidocaine hydrochloride 1 % Injectable Solution

Clinical Specifications

Proprietary Name
Lidocaine Hcl And Epi
Dosage Form
-
Usage Information
Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
FDA Application #
NDA006488
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-31-2022
Listing Expiration
12-31-2024
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1589-3 identifies a specific commercial package of 25 pouch in 1 case / 1 vial, multi-dose in 1 pouch (51662-1589-2) / 50 ml in 1 vial, multi-dose (51662-1589-1) of Lidocaine Hcl And Epi, labeled by Hf Acquisition Co Llc, Dba Healthfirst. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on July 31, 2022. The current certification is valid through December 31, 2024.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662158903. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1589-3
11-Digit CMS (5-4-2)
51662-1589-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.